USP18 induction regulates immunometabolism to attenuate M1 signal-polarized macrophages and enhance IL-4-polarized macrophages in systemic lupus erythematosus

Copyright © 2024 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 265(2024) vom: 01. Aug., Seite 110285
1. Verfasser: Lai, Jenn-Haung (VerfasserIn)
Weitere Verfasser: Wu, De-Wei, Huang, Chuan-Yueh, Hung, Li-Feng, Wu, Chien-Hsiang, Ho, Ling-Jun
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2024
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Immunometabolism Interferon Macrophage polarization Systemic lupus erythematosus USP18 Ubiquitin Thiolesterase EC 3.4.19.12 Interleukin-4 207137-56-2 mehr... USP18 protein, human Usp18 protein, mouse EC 3.4.19.- Reactive Oxygen Species Interferon-gamma 82115-62-6 IL4 protein, human Lipopolysaccharides Hypoxia-Inducible Factor 1, alpha Subunit
LEADER 01000caa a22002652c 4500
001 NLM373682514
003 DE-627
005 20250306073747.0
007 cr uuu---uuuuu
008 240617s2024 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2024.110285  |2 doi 
028 5 2 |a pubmed25n1244.xml 
035 |a (DE-627)NLM373682514 
035 |a (NLM)38880201 
035 |a (PII)S1521-6616(24)00394-2 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Lai, Jenn-Haung  |e verfasserin  |4 aut 
245 1 0 |a USP18 induction regulates immunometabolism to attenuate M1 signal-polarized macrophages and enhance IL-4-polarized macrophages in systemic lupus erythematosus 
264 1 |c 2024 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 19.07.2024 
500 |a Date Revised 22.07.2024 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2024 Elsevier Inc. All rights reserved. 
520 |a Effective treatment of systemic lupus erythematosus (SLE) remains an unmet need. Different subsets of macrophages play differential roles in SLE and the modulation of macrophage polarization away from M1 status is beneficial for SLE therapeutics. Given the pathogenic roles of type I interferons (IFN-I) in SLE, this study investigated the effects and mechanisms of a mitochondria localization molecule ubiquitin specific peptidase 18 (USP18) preserving anti-IFN effects and isopeptidase activity on macrophage polarization. After observing USP18 induction in monocytes from SLE patients, we studied mouse bone marrow-derived macrophages and showed that USP18 deficiency increased M1signal (LPS + IFN-γ treatment)-induced macrophage polarization, and the effects involved the induction of glycolysis and mitochondrial respiration and the expression of several glycolysis-associated enzymes and molecules, such as hypoxia-inducible factor-1α. Moreover, the effects on mitochondrial activities, such as mitochondrial DNA release and mitochondrial reactive oxygen species production were observed. In contrast, the overexpression of USP18 inhibited M1signal-mediated and enhanced interleukin-4 (IL-4)-mediated polarization of macrophages and the related cellular events. Moreover, the levels of USP18 mRNA expression showed tendency of correlation with the expression of metabolic enzymes in monocytes from patients with SLE. We thus concluded that by preserving anti-IFN effect and downregulating M1 signaling, promoting USP18 activity may serve as a useful approach for SLE therapeutics 
650 4 |a Journal Article 
650 4 |a Immunometabolism 
650 4 |a Interferon 
650 4 |a Macrophage polarization 
650 4 |a Systemic lupus erythematosus 
650 4 |a USP18 
650 7 |a Ubiquitin Thiolesterase  |2 NLM 
650 7 |a EC 3.4.19.12  |2 NLM 
650 7 |a Interleukin-4  |2 NLM 
650 7 |a 207137-56-2  |2 NLM 
650 7 |a USP18 protein, human  |2 NLM 
650 7 |a EC 3.4.19.12  |2 NLM 
650 7 |a Usp18 protein, mouse  |2 NLM 
650 7 |a EC 3.4.19.-  |2 NLM 
650 7 |a Reactive Oxygen Species  |2 NLM 
650 7 |a Interferon-gamma  |2 NLM 
650 7 |a 82115-62-6  |2 NLM 
650 7 |a IL4 protein, human  |2 NLM 
650 7 |a Lipopolysaccharides  |2 NLM 
650 7 |a Hypoxia-Inducible Factor 1, alpha Subunit  |2 NLM 
700 1 |a Wu, De-Wei  |e verfasserin  |4 aut 
700 1 |a Huang, Chuan-Yueh  |e verfasserin  |4 aut 
700 1 |a Hung, Li-Feng  |e verfasserin  |4 aut 
700 1 |a Wu, Chien-Hsiang  |e verfasserin  |4 aut 
700 1 |a Ho, Ling-Jun  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 265(2024) vom: 01. Aug., Seite 110285  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnas 
773 1 8 |g volume:265  |g year:2024  |g day:01  |g month:08  |g pages:110285 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2024.110285  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 265  |j 2024  |b 01  |c 08  |h 110285